A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Víctor Moreno, Ruth Perets, Tamar Peretz‐Yablonski, Nele Fourneau, Suzette Girgis, Yue Guo, Peter Hellemans, Raluca Verona, Natalia Pendás, Qi Xia, Ravit Geva, Emiliano Calvo
Topics & Concepts
MedicineChillsPharmacokineticsAdverse effectPharmacodynamicsInternal medicineGastroenterologyRenal cell carcinomaPharmacologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research